期刊文献+

氟伐他汀与普伐他汀治疗高脂血症疗效比较 被引量:5

Fluvastatin vs pravastatin in treating hyperlipidemia
下载PDF
导出
摘要 目的 :观察并比较氟伐他汀与普伐他汀的降脂疗效。方法 :氟伐他汀组 4 1例 (男性 2 2例 ,女性 19例 ,年龄 6 0a±s 8a) ,应用氟伐他汀 2 0~ 4 0mg ,po ,qn× 4wk。普伐他汀组 35例 (男性 2 0例 ,女性 15例 ,年龄 6 0a± 6a) ,应用普伐他汀 10mg ,po ,qn× 4wk。结果 :氟伐他汀降低TC的总有效率 92 % ,普伐他汀为 70 % (P <0 .0 5) ;氟伐他汀降低TG及升高HDL C的总有效率为 6 1%和 6 1% ,与普伐他汀的 73%和 6 9%相似 (P >0 .0 5)。 2组的不良反应发生率为 2 0 % (8/41)和 2 0 % (7/35)。结论 :氟伐他汀是一种安全、有效的降脂药物 ,且降低TC作用优于普伐他汀。 AIM: To observe and compare the antihyperlipidemia efficacy of fluvastatin vs pravasatin. METHODS: Fluvastatin group( n =41,M 22, F 19; age 60 a± s 8 a) was treated with fluvastatin 20 40 mg, po , qn for 4 wk. Pravastatin group( n =35, M 20, F 15; age 60 a±6 a) was treated with pravastatin 10 mg, po , qn for 4 wk. RESULTS: The total effective rate of fluvastatin for reducing TC was 92 %, it was higher than that of pravastatin 70 %( P <0.05). The total effective rates of flavastatin for reducing TG and raising HDL C were 61 % and 61 %, were similar to that of pravastatin 73 % and 69 %( P >0.05). Adverse reactions occurred in 8 patients of fluvastatin(20 %) and in 7 patients of pravastatin(20 %), but were mild in both groups. CONCLUSION: Fluvastatin is a safe and effective antihyperlipidemic drug, and fluvastatin is more effective than pravastatin in decreasing total cholesterol.
作者 何小玲
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2001年第3期165-167,共3页 Chinese Journal of New Drugs and Clinical Remedies
关键词 氟伐他汀 普伐他汀 高脂血症 治疗 疗效比较 fluvastatin pravastatin hyperlipidemia cholesterol triglycerides [
  • 相关文献

参考文献4

二级参考文献6

  • 1杜志民,新药与临床,1997年,16卷,63页
  • 2胡婉英,新药与临床,1997年,16卷,52页
  • 3姚桦,新药与临床,1997年,16卷,57页
  • 4徐济民,临床实用新药手册,1996年,296页
  • 5王维治,新药与临床,1995年,14卷,71页
  • 6李文贤,新药与临床,1993年,12卷,242页

共引文献17

同被引文献35

  • 1孔晓东.药物经济学:概念、方法和应用[J].国外医学(药学分册),1994,21(1):13-18. 被引量:429
  • 2王钟林.血脂调整剂的合理应用[J].临床内科杂志,1995,12(1):2-4. 被引量:8
  • 3裴奇,李佐军,阳国平,周于禄,易丹,黄琪,吴翠芳,刘世坤.高效液相色谱荧光检测法测定人体内血浆中氟伐他汀的浓度[J].中国新药与临床杂志,2006,25(10):756-758. 被引量:4
  • 4陈灏珠主编.实用内科学[M]:第十版[M].北京:人民卫生出版社,1998.1218.
  • 5Riegger G, Abletshauser C, Ludwig M, et al. The effect of flux' astatin on cardiac events in patients with symptomatic coronary artery disease during one year treatment[J] . Atherosclerosis,1999,144 ( 1 ) :263 - 270.
  • 6Downs JR,Clearfield M. Wels S. et al. Primary prevention of acute corenary events with lovastatin in men and women with average choles-terol levels, Results of AFCAPS/TexCAPS [ J ].JAMA, 1998,279(20) : 1615 - 1622.
  • 7LANCHOTE VL, ROCHA A, de AILUQUERQUE FU, et al.Stereoselective analysis of fluvastatin in human plasma for pharmacokinetic studies [J]. J Chromatogr B Biomed Sci Appl, 2001,765(1 ) : 81-88.
  • 8NAKASHIMA A, SAXER C, NIINA M, et al. Determination of fluvastatin and its five metabolites in human plasma using simple gradient reversed-phase high-performance liquid chromatography with ultraviolet detection [J]. J Chromatogr B Biomed Sei Appl,2001. 760( 1 ), 17-25.
  • 9TORESON H, ERIKSSON BM. Determination of fluvastatin enantiomers and the racemate in human blood plasma by liquid chromatography and fluorometric detection [J]. J Chromatogr A, 1996,729(1-2) : 13-18.
  • 10BARILLA D, PRASAD P, HUBERT M, et al. Steady-state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol XL [J]. Biopharm Drug Dispos, 2004, 25(2):51-59.

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部